|
NR. 4/2006
|
|
|
|
|
|
|
|
|
Zastosowanie
preparatu Avastin w leczeniu postaci wysiękowej degeneracji
plamki związanej z wiekiem, makulopatii cukrzycowej i
retinopatii cukrzycowej proliferacyjnej – wyniki badania
pilotażowego
The Use of Avastin in the Treatment of Exudative Form of
Age-related Macular Degeneration, Diabetic Macular Edema and
Proliferative Diabetic Retinopathy – Early Result of the Pilot
Study
Iwona Grabska-Liberek, Agnieszka
Nowosielska, Katarzyna Gurdziel
Oddział Kliniczny Okulistyki Centrum Medycznego Kształcenia
Podyplomowego
Samodzielnego Publicznego Szpitala Klinicznego im. prof. W.
Orłowskiego w Warszawie
P.o. kierownik: dr n. med. Iwona Grabska-Liberek |
|
|
|
|
|
|
|
| Summary: |
Purpose: The aim of this
paper is to describe the results of six week, open label,
pilot study of intravitreal Avastin administration in
cases of exudative form of age-related macular
degeneration, diabetic macular edema and proliferative
diabetic retinopathy.
Material and methods: There were 6 patients enrolled
into the trial, who all gave written consent. Avastin
was given only to one eye of each patient. The given
dosage was 1.25 mg/ 0.05ml. The drug administration took
place in operating room under the local anesthesia.
Results: All patients participating in the pilot study
gain some vision in the treated eye and remained stable
during 6 week follow-up period. However improvement in
case of AMD patients was limited. The best result was
achieved in diabetic patients.
Conclusions: Avastin seems to be save and effective drug
while used intravitreally. No major adverse event during
or up to 6 weeks after administration were noted. The
vision improvement in our opinion is mostly dependent on
the state of the basic disease.
Further studies are needed to assess the long-term
safety and efficacy of this promising drug. |
| |
|
| Key words: |
retinal laser treatment,
complications, side effects. |
|
|
|
|
|
|
|
|
